Vaccines Market Research Reports & Industry Analysis
Because of the large number of deadly diseases that have been eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements of the 20th century. Key issues in the global vaccine market today include unequal access to vaccines, supply chain disruptions, the use of vaccines to prevent pandemics and address bioterrorism, technological innovations, and vaccine hesitancy. Learn more about this critical field with the comprehensive selection of vaccine market research reports available on MarketResearch.com.
New Vaccines Market Data and Insights
- Find data on vaccine market size segmented by region, technology, distribution channel, type, route of administration, and disease.
- Gain a deep understanding of vaccine industry dynamics, market structure, growth outlook, and competitive landscape.
- Learn about influential government initiatives and new vaccination technologies that have highly promising results.
Your Source for Expert Data and Analysis
MarketResearch.com is a trusted research partner, backed by over two decades of experience. Our clients include top investment banks, management consulting firms, and leading multinational companies within the Fortune 500. Our team of research specialists is dedicated to guiding you at every step, ensuring you have the resources and insights you need to answer your toughest research questions. Browse our full list of vaccines industry reports today.
Vaccines Industry Research & Market Reports
-
Therapeutic Vaccines
... CAGR of 16.7% over the analysis period 2024-2030. Autoimmune Disease Vaccines, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$62.8 Billion by the end of the ... Read More
-
Hepatitis B Vaccines
... at a CAGR of 4.3% over the analysis period 2024-2030. Adult, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.7 Billion by the end of the ... Read More
-
Human Vaccines
... CAGR of 7.3% over the analysis period 2024-2030. Intramuscular & Subcutaneous, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$58.7 Billion by the end of the ... Read More
-
Swine Vaccines
... CAGR of 3.7% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. ... Read More
-
Pneumococcal Vaccines
... CAGR of 5.3% over the analysis period 2024-2030. Pneumococcal Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
Respiratory Disease Vaccines
... at a CAGR of 0.7% over the analysis period 2024-2030. Viral Vaccine, one of the segments analyzed in the report, is expected to record a 0.6% CAGR and reach US$60.0 Billion by the end of ... Read More
-
Cholera Vaccines
... CAGR of 8.4% over the analysis period 2024-2030. Killed Oral O1 and O139 Vaccine, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$86.4 Million by the ... Read More
-
Combination Vaccines
... CAGR of 9.8% over the analysis period 2024-2030. Pediatric Age Group, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$5.4 Billion by the end of the ... Read More
-
Brucellosis Vaccines
... CAGR of 3.5% over the analysis period 2024-2030. RB51 Vaccine, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$162.0 Million by the end of the analysis ... Read More
-
Anthrax Vaccine
... CAGR of 3.2% over the analysis period 2024-2030. Cell-Free PA Vaccines, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$8.4 Billion by the end of the ... Read More
-
Autogenous Vaccines
... CAGR of 3.6% over the analysis period 2024-2030. Bacterial Strain, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$108.6 Million by the end of the analysis ... Read More
-
Mumps Vaccines
... CAGR of 7.3% over the analysis period 2024-2030. Monovalent, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$483.5 Million by the end of the analysis period. ... Read More
-
Multivalent Vaccines
... CAGR of 9.0% over the analysis period 2024-2030. Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$9.9 Billion by the end of the analysis ... Read More
-
Rabies Vaccine
... CAGR of 3.8% over the analysis period 2024-2030. Chick Embryo Cells Rabies Vaccine, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$708.0 Million by the end ... Read More
-
H1N1 Vaccines
... CAGR of 5.4% over the analysis period 2024-2030. Intramuscular, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$1.1 Billion by the end of the analysis period. ... Read More
-
Conjugate Vaccines
... CAGR of 6.8% over the analysis period 2024-2030. Multivalent Conjugate Vaccines, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$21.0 Billion by the end of the ... Read More
-
Tetanus Toxoid Vaccine
... at a CAGR of 2.6% over the analysis period 2024-2030. Tetanus, Diphtheria, and Pertussis (Tdap), one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$1.7 Billion by ... Read More
-
Foot and Mouth Disease (FMD) Vaccine
... reach US$5.6 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Conventional Vaccines, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach ... Read More
-
Biodefense
... 4.2% over the analysis period 2024-2030. Anthrax, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$6.4 Billion by the end of the analysis period. Growth in ... Read More
-
Microneedle Flu Vaccine
... at a CAGR of 5.2% over the analysis period 2024-2030. Solid Microneedle, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$1.4 Billion by the end of ... Read More
-
Cat Vaccines
... CAGR of 8.1% over the analysis period 2024-2030. Modified / Attenuated Live Vaccines, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$965.1 Million by the end ... Read More
-
Respiratory Virus Vaccines
... at a CAGR of 5.1% over the analysis period 2024-2030. Inactivated / Killed, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$7.1 Billion by the end ... Read More
-
Hepatitis A Vaccines
... at a CAGR of 2.1% over the analysis period 2024-2030. Inactivated Vaccine, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$572.5 Million by the end of ... Read More
-
Avian Influenza Vaccine
... at a CAGR of 6.8% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$800.9 Million by the end of the ... Read More
-
Adenovirus Vaccines
... CAGR of 5.4% over the analysis period 2024-2030. Type 4 Vaccine, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$777.8 Million by the end of the ... Read More
Research Assistance
